Neoplasms Clinical Trials in Toronto, Ontario
44 recruitingToronto, Ontario, Canada
Showing 1–20 of 44 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 1Phase 2
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Neoplasms, Prostate
GlaxoSmithKline54 enrolled6 locationsNCT07332455
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled257 locationsNCT06841354
Recruiting
Phase 3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Neoplasms, Lung
GlaxoSmithKline420 enrolled114 locationsNCT07099898
Recruiting
Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled163 locationsNCT07164443
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled97 locationsNCT07225946
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting
LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
Lung Neoplasms
AstraZeneca60,000 enrolled2 locationsNCT07143110
Recruiting
Phase 1Phase 2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC81 enrolled17 locationsNCT06686394
Recruiting
Phase 1
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Neoplasms
GlaxoSmithKline158 enrolled26 locationsNCT05277051
Recruiting
Phase 2
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Breast NeoplasmsOvarian Neoplasms
GlaxoSmithKline30 enrolled25 locationsNCT04641247
Recruiting
Phase 1Phase 2
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
Colonic Neoplasms
University of Michigan Rogel Cancer Center1,200 enrolled13 locationsNCT00843375
Recruiting
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Colorectal Neoplasms
University Health Network, Toronto120 enrolled1 locationNCT02732860
Recruiting
Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients
Breast CancerMetastatic Breast CancerBreast Neoplasms+1 more
Sunnybrook Health Sciences Centre25 enrolled1 locationNCT04608357
Recruiting
Not Applicable
Non-operative Management for Locally Advanced Rectal Cancer
Rectal Neoplasms
Mount Sinai Hospital, Canada90 enrolled1 locationNCT03179540